Today’s stock market: Mankind Pharma’s share price opened 4.6% higher following its announcement of stake acquisitions in Bharat Serums and Vaccines Limited.
How old is the Mankind company?
History: Mankind Pharma was established in 1991 by brothers Ramesh C. Juneja and Rajeev Juneja, who initially invested ₹5,000,000. The company started its operations in 1995.
The share price of Mankind Pharma opened 4.6% higher at ₹2240.00 on the BSE compared to the previous close on Friday. However, the majority of the profits were given up after that.
Mankind Pharma has disclosed a definitive agreement to purchase complete ownership of Bharat Serums and Vaccines Limited (BSV) from Advent International, a prominent private equity firm.
Value of the deal
Mankind Pharma will acquire a 100% share in Bharat Serums & Vaccines Limited for around ₹13,630 crores. This amounts to a valuation of 23-24 times enterprise value by Ebitda (EV/Ebitda) per corporate presentation. EBITDA is an acronym for earnings before interest, taxes, depreciation, and amortization.
The deal will be funded by internal accruals as well as a combination of debt and equity. The transaction is anticipated to be completed in 3-4 months.
What is the number of employees at Mankind Pharma?
Mankind Pharma employs between 10,001 and 50,000 people in India. The company’s global headquarters are located in New Delhi, Delhi, India, and it also has offices in Gurgaon, Gurugram, and New Delhi.
Benefits:
Mankind Pharma stated that the acquisition of Bharat Serums and Vaccines will increase its footprint in high-entry portfolios and help it maintain its leadership in Women’s Health. In the Indian Pharma Market, we are ranked top in the Gynecology area.
What is the outlook for mankind’s stock?
According to analysts, the price objective for MANKIND is 2,315.50 INR, with a maximum estimate of 2,650.00 INR and a minimum estimate of 1,800.00 INR. Check back in a year to see if this prognosis comes true; in the meanwhile, monitor the MANKIND PHARMA LTD stock price chart and stay up to date on the latest MANKIND news and stock market developments.
Bharat Serums and Vaccines portfolio:
Bharat Serums and Vaccines’ domestic brand portfolio includes several significant names. The company has one brand worth more than ₹100 crore, three brands worth ₹50-100 crore, and eight brands worth ₹25-50 crore.
In fiscal year 24, Bharat Serums and Vaccines recorded margins of 23%. However, adjusted for one-time items, the figure was 28% in FY24, according to Mankind’s financial presentation.
During FY24, Bharat Serun And Vaccines generated ₹1,723 crore in revenue. Domestic markets accounted for 54% of revenues, while branded international sales made up 46%.
Mankind Financials:
Mankind’s FY24 sales were ₹10,335 crore, with an EBITDA of ₹2,550 crore, resulting in an EBITDA margin of 24.7%. The acquisition of Bharat Serum And Vaccines will add over 40 products to Mankind’s portfolio, valued at over ₹50 crore.
value of around INR 13,630 crores, subject to closing adjustments.
Should I buy Mankind Pharma stock?
Mankind Pharma has a TTM P/E ratio of 48.18, compared to the sector’s P/E of 31.07. 13 analysts have begun coverage of Mankind Pharma. Three analysts have given it a strong buy recommendation, while five have given it a buy rating. One analyst has given the stock a sell rating.
